-
Mashup Score: 0
Read Volume 132 Issue Supplement 1 of Blood.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Oral and Poster Abstracts 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II Luciano J. Costa, MD, PhD1, Nicholas Burwick, MD2, Andrzej Jakubowiak, MD, PhD3, Jonathan L. Kaufman, MD4, Fernando Cabanillas, MD5, Monique Dail, PhD6*, Sudeep Karve7*, Abdullah A. Masud, PhD8*, Xiaoqing Yang, PhD7*, Orlando F. Bueno7, Sarah Mudd, PhD8*,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
MT @Rfonsi1 [12/6/20] Ven+Kd. ORR 92% in t(11;14). 15% MRD- (5). Critical study for those using less bortezomib. https://t.co/UXqeimRMrV #NCT02899052 #mmsm #mmMRD #oncorad https://t.co/A0wtHtH7SF
-
Assessment of MRD By NGS & FDG-PET in Pts w/ Relapsed/Refractory Multiple Myeloma Treated w/ Venetoclax in Combination w/ Carfilzomib and Dexamethasone (Kd-Ven) [Dec 6, 2020] @End_myeloma et al. #ASH20 Abst 2251 https://t.co/UXqeimRMrV #NCT02899052 #mmsm #mmMRD #oncorad
-
-
Mashup Score: 3
Oral and Poster Abstracts 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II Luciano J. Costa, MD, PhD1, Nicholas Burwick, MD2, Andrzej Jakubowiak, MD, PhD3, Jonathan L. Kaufman, MD4, Fernando Cabanillas, MD5, Monique Dail, PhD6*, Sudeep Karve7*, Abdullah A. Masud, PhD8*, Xiaoqing Yang, PhD7*, Orlando F. Bueno7, Sarah Mudd, PhD8*, Jeremy A….
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
MT @Rfonsi1 [12/6/20] Ven+Kd. ORR 92% in t(11;14). 15% MRD- (5). Critical study for those using less bortezomib. https://t.co/UXqeimRMrV #NCT02899052 #mmsm #mmMRD #oncorad https://t.co/A0wtHtH7SF
-
Assessment of MRD By NGS & FDG-PET in Pts w/ Relapsed/Refractory Multiple Myeloma Treated w/ Venetoclax in Combination w/ Carfilzomib and Dexamethasone (Kd-Ven) [Dec 6, 2020] @End_myeloma et al. #ASH20 Abst 2251 https://t.co/UXqeimRMrV #NCT02899052 #mmsm #mmMRD #oncorad https://t.co/KY5AUZXJzB
-
-
Mashup Score: 2
Oral and Poster Abstracts 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II Luciano J. Costa, MD, PhD1, Nicholas Burwick, MD2, Andrzej Jakubowiak, MD, PhD3, Jonathan L. Kaufman, MD4, Fernando Cabanillas, MD5, Monique Dail, PhD6*, Sudeep Karve7*, Abdullah A. Masud, PhD8*, Xiaoqing Yang, PhD7*, Orlando F. Bueno7, Sarah Mudd, PhD8*, Jeremy A….
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
MT @Rfonsi1 [12/6/20] Ven+Kd. ORR 92% in t(11;14). 15% MRD- (5). Critical study for those using less bortezomib. https://t.co/UXqeimRMrV #NCT02899052 #mmsm #mmMRD #oncorad https://t.co/A0wtHtH7SF https://t.co/Chp6PL3xbO
-
Assessment of MRD By NGS & FDG-PET in Pts w/ Relapsed/Refractory Multiple Myeloma Treated w/ Venetoclax in Combination w/ Carfilzomib and Dexamethasone (Kd-Ven) [Dec 6, 2020] @End_myeloma et al. #ASH20 Abst 2251 https://t.co/UXqeimRMrV #NCT02899052 #mmsm #mmMRD #oncorad https://t.co/IsY19hYzo0
-
-
Mashup Score: 0Webprogram Unavailable - 3 year(s) ago
60th Annual Meeting and Exposition (December 1-4, 2018) Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Ph2 Venetoclax / Carfilzomib / Dex (Kd-VEN) in RRMM [Dec 2, 2018] - @End_myeloma et al. #ASH18 303 https://t.co/cZO41lDmoa #mmsm #NCT02899052 - t(11;14) n=8 100% ORR, 88% >= VGPR https://t.co/ZafxWk7WWw
-
-
Mashup Score: 4Advocate Aurora cancer clinics are first in Wisconsin to join multiple myeloma clinical trial | Research | Aurora Health Care - 3 year(s) ago
The study will evaluate the investigative drug venetoclax in combination with anti-cancer drug carfilzomib and dexamethasone in patients with multiple myeloma.
Source: www.aurorahealthcare.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
. @Aurora_Cancer @AdvocateAurora clinics are first in Wisconsin to join multiple myeloma clinical trial. Study will evaluate the investigational drug venetoclax in combo with carfilzomib dex (Kd) [Feb 23, 2021] https://t.co/0SzOIyTHuL #mmsm #NCT02899052 https://t.co/WuFdSlmHIm
-
Ph2 Venetoclax / Carfilzomib / Dex (Kd-VEN) in RRMM [Dec 2, 2018] - @End_myeloma et al. #ASH18 303 https://t.co/cZO41lDmoa #mmsm #NCT02899052 - t(11;14) n=8 100% ORR, 88% >= VGPR